ENGY yields 20000000.00% · ABBV yields 3.06%● Live data
📍 ENGY pulled ahead of the other in Year 1
Combined, ENGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENGY + ABBV for your $10,000?
Central Energy Partners LP, through its subsidiary, Regional Enterprises, Inc., provides liquid bulk storage, trans-loading, and transportation services for hazardous chemicals and petroleum products in the United States. It transports hazardous liquid products, such as aluminum sulfate solution, hydrochloric and sulfuric acid, sodium hydroxide, aqua ammonia, sodium bisulfate, and fuel blends; and non-hazardous materials, including crude tall oil, No. 2 oil, No. 6 oil, asphalt additives, micro-c, and vacuum gas oil in the states of Virginia, North Carolina, South Carolina, Georgia, Tennessee, Maryland, Pennsylvania, and Delaware. The company also offers tank storage and terminal services. As December 31, 2014, it had a fleet of 15 leased tractors, 5 owned tractors, and 36 tanker units for transportation services. Central Energy GP LLC serves as the general partner of Central Energy Partners LP. The company was formerly known as Rio Vista Energy Partners L.P. and changed its name to Central Energy Partners LP in December 2010. Central Energy Partners LP was founded in 2003 and is based in Dallas, Texas.
Full ENGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.